StemCell Therapy

Saint-Herblain (France), June 7, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will present on its single-shot chikungunya vaccine candidate VLA1553 on June 9, 2022 at the 8th Northern European Conference on Travel Medicine (NECTM8) in Rotterdam.

Read more:
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8

PRESS RELEASE

Continue reading here:
AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the...

CRANBURY, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that preliminary results from the ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors harboring a p53 Y220C mutation demonstrated anti-tumor efficacy across multiple tumor types with an acceptable safety profile. PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation in solid tumors.

Read more here:
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C...

Leuven, BELGIUM, Boston, MA, US – JUNE 7, 2022 – Oxurion NV (Euronext Brussels: OXUR), a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies in patients with retinal disorders including diabetic macular edema, today delivered a preclinical presentation evaluating the pharmacokinetic properties of THR-149 at KININ2022, held in Annecy, France, June 5-8, 2022.

Read the original here:
Oxurion Announces Preclinical Presentation on THR-149 at KININ2022

New Super-Premium Natural Pet Food Brand from Better Choice Company Targets Millennial and Gen Z Pet Parents New Super-Premium Natural Pet Food Brand from Better Choice Company Targets Millennial and Gen Z Pet Parents

Read this article:
Halo Pet Launches Multi-Million Dollar Marketing Campaign to Celebrate the World's Best Kids: Your Pet

TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be presenting and exhibiting at Outsourcing in Clinical Trials: Medical Devices USA 2022, June 8-9 in Irvine, CA.

Go here to read the rest:
Axiom Presenting “Safety First: How Integrated Clinical Platforms Offer a Critical Advantage in Managing the Various Points to Control Safety” at...

Daix (France), Long Island City (New York, United States), June 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that it will join the Euronext Tech Leaders initiative, a new Euronext segment comprised of more than 100 high-growth and leading Tech companies across Europe.

View original post here:
Inventiva joins the Euronext Tech Leaders segment

BOSTON and LOUISVILLE, Ky., June 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented additional data and analyses from its Phase 2 trial of FCR001 and other studies of its Facilitated Allo-HSCT Therapy platform at the 2022 American Transplant Congress (ATC).

Visit link:
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

Thursday, June 16th @ 10:30 a.m. ET Thursday, June 16th @ 10:30 a.m. ET

Excerpt from:
Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference at 4:00 p.m. PT on Tuesday, June 14, 2022. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

See more here:
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14 at 10:40am PT.

Read more:
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

Montrouge, France, June 7, 2022

Read more here:
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

SAN FRANCISCO, June 07, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. Eastern Time in New York City, NY.

Go here to read the rest:
Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET

FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Original post:
Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic...

Orphazyme A/SCompany announcementNo. 30/2022                                                                        Annual reportwww.orphazyme.com Company Registration No. 32266355

Read the original:
Orphazyme Announces Publication of 2021 Financial Results and Annual Report

Orphazyme A/SCompany announcementNo. 31/2022www.orphazyme.comCompany Registration No. 32266355

See the rest here:
Notice to convene Annual General Meeting

Basel, 8 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for the CD20xCD3 T-cell engaging bispecific antibody Lunsumio® (mosunetuzumab), for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. Lunsumio is an off-the-shelf therapy that is readily available, so people do not have to wait to start treatment.

Read more here:
European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma

ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2022 at 16.00 EEST

See more here:
Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2022 at 16.00 EEST

More:
Orion Corporation: Managers’ transactions – Veli-Matti Mattila

ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2022 at 16.00 EEST

See the rest here:
Orion Corporation: Managers’ transactions – Ari Lehtoranta